SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending after a massive post-earnings surge driven by strong data center demand and optimism surrounding its turnaround narrative, with community members actively discussing a historic short squeeze and debating the company's valuation versus its long-term AI growth potential. While some traders are celebrating significant gains and pointing to institutional momentum, others remain cautious, warning of potential profit-taking and the risks of chasing the stock's rapid appreciation.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging in after-hours trading as a sympathy play driven by Intel's strong earnings beat and positive guidance, which has reignited momentum across the semiconductor sector. While the community is split between bullish investors riding a massive trend and bears warning of an overextended valuation, the primary focus remains on the AI infrastructure buildout and a tightening supply of high-performance chips.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors react to a major consolidation event, specifically the Greenland government's approval for the company to secure a 92.5% controlling interest in the Tanbreez mining project. The community is actively discussing the strategic appointment of a new Tanbreez CEO with local expertise, with many speculating this shift toward operational development will trigger significant upside, while others debate the impact of a newly announced $60 million private placement on the stock's short-term price action.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is gaining investor attention following a major shareholder-approved merger with Warner Bros. Discovery and the securing of $24 billion in funding from Middle East wealth funds. Community discussions are currently dominated by the implications of this media consolidation, including potential debt restructuring, executive compensation debates, and the strategic addition of warrants as a value-added incentive for current shareholders.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are actively debating the sustainability of the semiconductor sector's parabolic rally, with many traders using $SOXS as a tactical hedge against overextended market conditions despite ongoing frustration over relentless sector gains. The community remains deeply divided, with some betting on a long-overdue mean reversion while others emphasize that shorting such a momentum-driven sector carries significant risk due to rapid decay and continued institutional support.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc. is experiencing extreme volatility and heavy retail interest following a major legal victory where a federal jury awarded the company significant damages for deceptive business practices by a competitor. While bulls are anticipating a short squeeze and institutional rerating based on the potential financial windfall, bears and cautious traders are skeptical about the enforceability of the payout and the stock's long-term sustainability.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending following shareholder approval of a massive merger with Paramount Skydance, a deal that aims to consolidate media assets despite lingering concerns from industry figures and regulators. The community is actively debating the implications of the leadership's executive compensation packages and the potential long-term impact on content strategy and competitive positioning in the streaming market.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors react to quarterly earnings that highlighted progress in pilot battery production, new partnerships, and expansion into AI data center and defense markets. The community is actively debating the stock's long-term potential as a solid-state battery leader versus concerns over its path to profitability, with many traders closely monitoring high volatility, heavy trading volume, and a significant short interest that could spark further price swings.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a community-driven meme project that encourages a high-risk, "no-roadmap" investment philosophy aimed at rapid growth. Investors are actively discussing the token's low market cap and the developer's frequent airdrops, while rallying to push the asset through its bonding curve and onto major tracking platforms.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending due to extreme volatility and a parabolic rally fueled by intense AI demand and market speculation, drawing fierce debate between bulls who anticipate further gains and bears calling for a correction. The community is actively discussing the stock's massive year-to-date performance, the sustainability of the semiconductor super-cycle, and the risks of leverage as traders attempt to time a potential blow-off top.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Grows By 19.4%

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 16,157,271 shares, an increase of 19.4% from the March 15th total of 13,534,910 shares. Approximately 18.1% of the...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm...

C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies

C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in milestones plus royalties. See the details.read more...

<ul class="summary-bullets"><li>C4&nbsp;Therapeutics is also eligible to earn tiered royalties on future product sales.</li><li>C4 and Roche will focus on developing emerging cancer treatments using degrader-antibody conjugates and targeted protein degradation processes.</li><li>The companies will work together on two programs to develop the new cancer treatments.&nbsp;</li></ul>Shares of C4 Therapeutics, Inc. (CCCC) reversed pre-market gains to edge 2% lower on Thursday, after the company expanded its partnership with Swiss pharmaceutical company Roche to develop cancer treatments.C4 Therapeutics said the new collaboration will focus on developing emerging cancer treatments using&nbsp;a degrader-antibody conjugate (DAC) and targeted protein degradation (TPD) processes.&nbsp;“Our new collaboration leverages C4T’s ability to design highly catalytic and selective degraders, as well as degrader payloads for DACs, alongside Roche’s extensive experience developing ADCs with specific binding. Together, these capabilities build a powerful new modality that can offer transformative medicines for patients,” said Andrew Hirsch, President and CEO of C4 Therapeutics.<h2 class="st-heading-2">C4 Could Earn Up To $1 Billion</h2>The companies will work together on two programs to develop new cancer treatments. C4&nbsp;Therapeutics&nbsp;will design the drug components using its TORPEDO platform, which uses advanced tools and AI to target harmful proteins.&nbsp;&nbsp;Roche will create the antibodies and combine them with the drug. Roche will also handle testing, development, and sales.&nbsp;C4&nbsp;Therapeutics&nbsp;will receive a $20 million upfront payment for the two programs, with the potential for additional payments if Roche opts to include a third target. The agreement also includes near-term discovery milestones, while total milestone payments could exceed $1 billion. Additionally, the firm is eligible to earn tiered royalties on future product sales.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the reversal after the opening bell, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/CCCC">CCCC</a> flipped to ‘extremely bullish’ from&nbsp; ‘bearish’ a day earlier, amid ‘high’ message volumes.One user said that, based on the contract, the stock should be around $4 to $5. It is currently around $2.8.<stembedurl>https://stocktwits.com/intrader/message/649802478</stembedurl>Another bullish user highlighted the company’s runway until 2028.<stembedurl>https://stocktwits.com/intrader/message/649810594</stembedurl>The stock has shot up more than 35% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside

Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments.

Equity

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 13,534,910...

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to their sector so far this year.

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have been given an average rating of "Moderate Buy" by the seven ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have i...

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling...

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays' 28th Annual Global Healthcare Conference, highlighting...

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

C4 Therapeutics (NASDAQ:CCCC) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program...

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

CCCC
C4 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CCCC News

CCCCC4 Therapeutics Inc